전립선암 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The prostate cancer diagnostics market is predicted to grow from USD 7.66 billion in 2026 growing at a CAGR of 8.8% to make up USD 16.32 billion in 2035.

Prostate cancer diagnostics play a critical role in early detection, risk stratification, treatment planning, and disease monitoring. Healthcare providers are increasingly focusing on identifying clinically significant cancers while reducing unnecessary biopsies and overtreatment. As prostate cancer exhibits substantial biological heterogeneity, diagnostic innovation is shifting toward highly specific biomarker-based tests and advanced imaging modalities that enable more accurate patient management. The integration of genomic profiling, liquid biopsy technologies, artificial intelligence (AI), and precision medicine approaches is transforming the prostate cancer diagnostic landscape.

Market Drivers

Growing Adoption of Precision Oncology

Precision medicine is increasingly influencing prostate cancer management. Clinicians now rely on genomic and molecular biomarkers to guide treatment decisions, predict disease progression, and identify patients most likely to benefit from targeted therapies. This trend is increasing demand for advanced molecular diagnostic solutions.

Expanding Aging Population

The incidence of prostate cancer rises significantly with age. As global populations continue aging, healthcare systems are witnessing increasing screening volumes and growing demand for accurate diagnostic technologies capable of supporting early intervention.

Rising Demand for Improved Risk Stratification

Traditional PSA-based screening often leads to false positives and unnecessary biopsies. Healthcare providers are increasingly adopting advanced risk stratification technologies that improve diagnostic specificity and help distinguish aggressive cancers from indolent disease.

Increasing Adoption of Multiparametric MRI

Multiparametric MRI has become an important diagnostic tool because it provides superior visualization of prostate lesions before invasive procedures. Its use improves biopsy targeting and helps reduce unnecessary interventions.

Market Restraints

Concerns Regarding False Positives

PSA testing continues to face limitations related to specificity. False-positive results may lead to unnecessary biopsies, patient anxiety, and increased healthcare expenditures.

Regulatory and Validation Requirements

Regulatory authorities increasingly require strong clinical validation and evidence of clinical utility before approving new diagnostic technologies. These requirements can extend commercialization timelines and increase development costs.

High Cost of Advanced Diagnostics

Genomic testing, molecular diagnostics, and advanced imaging technologies often require significant investment, limiting accessibility in some healthcare settings and emerging markets.

Market and Technology Insights

The global prostate cancer diagnostics market can be segmented by product & service, diagnostic technology, application, end user, and geography.

By product & service, the market includes:

• Instruments
• Reagents & Consumables
• Software & Diagnostic Analytics Solutions
• Diagnostic Testing Services

Reagents and consumables account for a substantial portion of market revenue because of recurring testing demand across diagnostic laboratories and healthcare facilities.

By diagnostic technology, the market comprises:

• Prostate-Specific Antigen (PSA) Testing
• Free PSA and PSA Derivative Testing
• Prostate Health Index (PHI) Testing
• PCA3 Testing
• Genomic and Molecular Diagnostics
• Liquid Biopsy Testing
• Multiparametric MRI (mpMRI)
• Tissue Biopsy-Based Diagnostics

Genomic diagnostics, liquid biopsy technologies, and advanced imaging modalities are expected to experience significant growth as healthcare providers seek greater diagnostic accuracy and personalized treatment pathways.

By application, the market includes:

• Screening and Early Detection
• Disease Diagnosis and Confirmation
• Risk Stratification
• Treatment Selection and Companion Diagnostics
• Disease Monitoring and Recurrence Detection

Early detection remains a key application area, while companion diagnostics and recurrence monitoring continue gaining importance in precision oncology.

By end user, the market serves:

• Hospitals
• Diagnostic Laboratories
• Cancer Centers
• Academic & Research Institutes
• Other End Users

Diagnostic laboratories and cancer centers continue expanding their molecular testing capabilities to support increasing demand for precision oncology services.

Market Trends

Several emerging trends are reshaping the prostate cancer diagnostics landscape:

• Expansion of liquid biopsy technologies.
• Increased use of genomic and molecular biomarker testing.
• Growing adoption of AI-assisted imaging analysis.
• Wider implementation of multiparametric MRI.
• Development of minimally invasive diagnostic solutions.
• Increasing integration of precision medicine into routine clinical workflows.
• Expansion of digital pathology and automated diagnostic analytics.

Regional Insights

North America

North America remains the largest market due to advanced healthcare infrastructure, widespread screening programs, extensive precision medicine initiatives, and strong adoption of genomic diagnostics. The United States continues to lead innovation and commercialization in prostate cancer diagnostics.

Europe

Europe maintains a significant market share supported by strong healthcare systems, increasing use of mpMRI, growing precision oncology adoption, and expanding molecular testing capabilities.

Asia-Pacific

Asia-Pacific is expected to experience the fastest growth because of rising healthcare investments, growing awareness of cancer screening, increasing incidence of prostate cancer, and expanding access to advanced diagnostics. China, Japan, India, South Korea, and Australia are major contributors to regional growth.

Latin America and Middle East & Africa

These regions are gradually improving diagnostic access through healthcare modernization, infrastructure development, and increased investment in cancer care programs.

Competitive Landscape

The market is characterized by continuous innovation in molecular diagnostics, genomic testing, imaging technologies, and AI-enabled diagnostic platforms.

Key companies include:

• Roche Diagnostics
• Exact Sciences Corporation
• Myriad Genetics
• Bio-Techne Corporation
• OPKO Health
• MDxHealth
• Thermo Fisher Scientific
• QIAGEN
• Danaher Corporation
• Abbott Laboratories
• Natera
• Veracyte

Companies continue investing in liquid biopsy development, AI-powered diagnostics, genomic profiling, and companion diagnostic solutions to strengthen their competitive positions.

Future Outlook

The future of the prostate cancer diagnostics market will be increasingly centered on precision-driven diagnostic pathways. Liquid biopsy technologies, AI-enhanced imaging, molecular biomarkers, and genomic profiling are expected to become integral components of routine clinical practice. Healthcare systems are seeking to balance early detection with avoidance of unnecessary interventions, creating significant opportunities for innovative multi-modal diagnostic platforms.

Conclusion

The Global Prostate Cancer Diagnostics Market is expected to witness strong growth through 2035, supported by rising prostate cancer incidence, expanding precision oncology adoption, and continued advances in molecular diagnostics and imaging technologies. While challenges related to cost, reimbursement, and clinical validation remain, innovations in genomic testing, liquid biopsy, AI-enabled diagnostics, and advanced imaging are expected to create substantial opportunities for diagnostic developers, healthcare providers, researchers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global prostate cancer diagnostics market.
• Detailed evaluation of diagnostic technologies and emerging innovations.
• Analysis of market dynamics, competitive strategies, and future opportunities.
• Insights into precision oncology, liquid biopsy, AI, and molecular diagnostics.
• Valuable resource for healthcare providers, diagnostic manufacturers, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, competitive benchmarking, product development strategy, precision medicine planning, commercialization strategy, partnership evaluation, investment analysis, regulatory planning, and long-term business decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
• Analysis by Product & Service, Diagnostic Technology, Application, End User, and Geography
• Evaluation of PSA testing, PHI testing, PCA3 testing, genomic diagnostics, liquid biopsy, mpMRI, and tissue biopsy-based diagnostics
• Assessment of screening, diagnosis, risk stratification, treatment selection, and recurrence monitoring
• Competitive analysis of leading companies and emerging diagnostic technologies through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Prostate Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Diagnostic Needs
• 3.8 Epidemiology and Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Screening and Testing Volume Analysis
• 3.11 Patient Journey Analysis
• 3.12 Prostate Cancer Screening Landscape
• 3.13 Precision Oncology Diagnostics Overview

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Prostate Cancer Diagnostics
• 6.2 Product Innovation Analysis
• 6.3 Liquid Biopsy Advancements
• 6.4 Molecular and Genomic Biomarker Developments
• 6.5 Multiparametric Imaging Innovations
• 6.6 Clinical Trial Analysis
• 6.7 Pipeline Analysis
• 6.8 AI Integration in Prostate Cancer Detection and Risk Stratification
• 6.9 Digital Pathology and Diagnostic Workflow Integration
• 6.10 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Prostate Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Screening versus Diagnostic Testing
• 8.7 Analysis by End User

9. Prostate Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product & Service
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software & Diagnostic Analytics Solutions
  • 9.1.4 Diagnostic Testing Services
• 9.2 By Diagnostic Technology
  • 9.2.1 Prostate-Specific Antigen (PSA) Testing
  • 9.2.2 Free PSA and PSA Derivative Testing
  • 9.2.3 Prostate Health Index (PHI) Testing
  • 9.2.4 PCA3 Testing
  • 9.2.5 Genomic and Molecular Diagnostics
  • 9.2.6 Liquid Biopsy Testing
  • 9.2.7 Multiparametric MRI (mpMRI)
  • 9.2.8 Tissue Biopsy-Based Diagnostics
• 9.3 By Application
  • 9.3.1 Screening and Early Detection
  • 9.3.2 Disease Diagnosis and Confirmation
  • 9.3.3 Risk Stratification
  • 9.3.4 Treatment Selection and Companion Diagnostics
  • 9.3.5 Disease Monitoring and Recurrence Detection
• 9.4 By End User
  • 9.4.1 Hospitals
  • 9.4.2 Diagnostic Laboratories
  • 9.4.3 Cancer Centers
  • 9.4.4 Academic & Research Institutes
  • 9.4.5 Other End Users

10. Prostate Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Prostate Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 China
• 11.10 Japan
• 11.11 South Korea
• 11.12 Australia
• 11.13 India
• 11.14 Brazil
• 11.15 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd
• 13.2 Exact Sciences Corporation
• 13.3 Myriad Genetics, Inc.
• 13.4 Bio-Techne Corporation
• 13.5 OPKO Health, Inc.
• 13.6 MDxHealth SA
• 13.7 Thermo Fisher Scientific Inc.
• 13.8 QIAGEN N.V.
• 13.9 Danaher Corporation
• 13.10 Abbott Laboratories
• 13.11 Siemens Healthineers AG
• 13.12 Bio-Rad Laboratories, Inc.
• 13.13 Veracyte, Inc.
• 13.14 Genomic Health, Inc.
• 13.15 Natera, Inc.

14. Prostate Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Forecast by Instruments
• 14.2 Forecast by Reagents & Consumables
• 14.3 Forecast by Software & Diagnostic Analytics Solutions
• 14.4 Forecast by Diagnostic Testing Services
• 14.5 Forecast by PSA-Based Testing
• 14.6 Forecast by Genomic and Molecular Diagnostics
• 14.7 Forecast by Multiparametric MRI Diagnostics
• 14.8 Forecast by Liquid Biopsy Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends